Farmakiotis; MD Anderson Cancer Ctr., Houston, TX. P. Sabo L. Ford Lin Kumar

138 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------------------------------------------------------------------------------------ Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 161A Poster Session Clinical Pharmacology of Antiviral and Anti-Tubercu- losis Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1243 PharmacokineticPharmacodynamic Model for Neuramini- dase Inhibitor Oseltamivir in the Ferret K. Yang 1,2 , G. Rao 1,2 , M. Reddy 2 , C. Pamulapati 2 , B. M. Marathe 3 , E. A. Govorkova 3 , C. R. Rayner 2 , A. Forrest 1 ; 1 SUNY Buffalo, Buffalo, NY, 2 Roche, Nutley, NJ, 3 St. Jude Children’s Res. Hosp., Memphis, TN. A-1244 Population Pharmacokinetics PPK of Oseltamivir in Pedi- atric and Adult Subjects

M. A. Kamal

1 , S. A. Van Wart 2 , C. R. Rayner 1 , V. Subramoney 1 , D. K. Reynolds 2 , C. C. Bulik 2 , P. F. Smith 1 , S. M. Bhavnani 2 , A. Forrest 2 ; 1 Hoffman-LaRoche, Nutley, NJ, 2 ICPD, Latham, NY. A-1245 A Prospective, Open-Label Study of the Pharmacokinetics, Safety and Pharmacodynamics of Oseltamivir in Infants 1 Year with Influenza

B. Rath

1 , B. Clinch 2 , D. Abadir 3 , J. Brzostek 4 , C. Chappey 5 , A. Charoin- Pannier 6 , K. Klumpp 3 , V. Niranjan 7 , X. Tong 3 , M. Wollenhaupt 6 , C. R. Rayner 8 ; 1 Charite Univ. Med. Ctr., Berlin, Germany, 2 Roche Products Ltd, Welwyn, United Kingdom, 3 Hoffmann-La Roche, Inc., Nutley, NJ, 4 Zespol Opieki Zdrowotnej w Debicy, Debica, Poland, 5 Genentech, Inc., South San Francisco, CA, 6 F. Hoffmann-La Roche Ltd, Basel, Switzerland, 7 RxMD, Chennai, India, 8 Roche Products Pty Ltd, Melbourne, Australia. A-1246 Intravenous Zanamivir Has No Effect on Cardiac Repolar- ization in Healthy Subjects P. Patel, Y. Lou, S. Weller, J. Gan, E. Gould, A. Peppercorn; GlaxoSmith- Kline, Research Triangle Park, NC. A-1247 Improved Bioavailability and Mitigated Food Effect for Asunaprevir ASV Utilizing a Lipid-Based Formulation: Similar Exposure with 100mg BID Softgel Capsule SGC Relative to 200mg BID of Phase 2 Tablet

T. Eley

1 , P. Chan 2,1 , O. Sverdlov 2 , B. He 2 , B. Bedford 2 , H. Kandoussi 2 , C. Vema-Varapu 2 , R. Perrone 2 , K. Sims 2 , I. Chang 2 , R. J. Bertz 2 ; 1 Bristol- Myers Squibb, Princeton, NJ, 2 BMS, Princeton, NJ. POSTER WALK Tuesday, September 11 | 11:15 a.m. - 12:15 p.m. | Halls A-C New Developments in Transplantation Convener: Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Presentations: Refractory KPC Carbapenemase-Producing Klebsiella pneu- moniae Bacteremia is Tolerated by Solid Organ Transplant Patients SOT Pts

C. Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.

Chronic High EBV Load Carriage Has Low Predictive Value to Detect Post-Transplant Lymphoproliferative Disorder PTLD in Solid-Organ Transplant Recipients

C. Gardiol; Univ. Hosp. Ctr. of Lausanne, Lausanne, Switzerland.

Risk Factors and Outcomes of Bacteremia Caused by Drug- Resistant ESKAPE Pathogens in Solid Organ Transplant SOT Recipients

M. Bodro; IDIBELL Biomedical Res. Inst., Hosp.Llobregat. Barcelona, Spain.

The Molecular Epidemiology of a Respiratory Syncytial Virus Outbreak Among Oncology and Hematopoietic Stem Cell Transplant HSCT Patients

H. Y. Chu; Univ. of Washington, Seattle, WA.

Diagnosis of Invasive Aspergillosis and Mucormycosis guided by PCR Assays from Bronchoalveolar Lavage Fluid in Allogenic Stem Cell Recipients

H. Lellek; Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany.

Tuesday, September 11 | 12:15 p.m. - 1:15 p.m. | Halls A-C Fungal Infections at the Bedside Convener: John Perfect, MD - Interim Chief, Division of Infectious Diseases and International Health Duke Univ. Med. Ctr., Durham, NC. Presentations: The Clinical Course Following the Use of Corticosteroids for Symptomatic Relief of Primary Pulmonary Coccidioidomycosis in Immunocompetent Persons

N. Azadeh; Mayo Clinic Arizona, Phoenix, AZ.

Effectiveness of Posaconazole Vs Fluconazole as Antifungal Prophylaxis in Hematology-Oncology Patients at Duke University Hospital DUH 2004-2010

H. C. Kung; Duke Clinical Res. Inst., Durham, NC.

Pilot Prospective Study of High Dose 10 mgkgd Liposomal Amphotericin B L-AmB for the Initial Treatment of Mucor- mycosis: “AMBIZYGO” Trial

F. Lanternier; Hosp. Necker Enfants malades, Paris, France; Inst. Pasteur, Paris, France.

Systemic Candidiasis Increased Mortality in ICU Infected Patients with Cirrhosis

H. Dupont; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens, France.

The Tolerability of Amphotericin B Lipid Complex Formula- tion in Patients With Severe Infusion Reactions to Liposomal Amphotericin B

D. Farmakiotis; MD Anderson Cancer Ctr., Houston, TX.

139 TUESDAY SCIENTIFIC SESSIONS Final Program A-1248 Cytochrome P450 CYP Interactions with the HCV Protease Inhibitor BI 201335 in Healthy Volunteers

J. P. Sabo

1 , A. D. Kashuba 2 , C. H. Ballow 3 , M. Haschke 4 , C. Yong 1 , T. R. MacGregor 1 , Y. Li 1 , J. Kort 1 ; 1 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, 2 Univ. of North Carolina, Chapel Hill, NC, 3 Buffalo Clinical Res. Ctr., Buffalo, NY, 4 Univ. Hosp. Basel, Basel, Switzerland. A-1249 Lack of Pharmacokinetic PK Interaction Between Rilpivirine and the Integrase Inhibitors Dolutegravir and SGSK1265744

S. L. Ford

1 , E. Gould 1 , S. Chen 1 , D. Margolis 1 , W. Spreen 1 , H. Crauwels 2 , S. Piscitelli 1 ; 1 GlaxoSmithKline, Research Triangle Park, NC, 2 Janssen RD, Beerse, Belgium. A-1250 Pharmacokinetics of Cobicistat-Boosted Elvitegravir Administered in Combination with Methadone or BuprenorphineNaloxone R. D. Bruce 1 , P. Winkle 2 , J. Custodio 3 , X. Ying 4 , M. Rhee 3 , J. Andrews 3 , B. P. Kearney 3 , S. Ramanathan 3 ; 1 Yale Univ., New Haven, CT, 2 Anaheim Clinical Trials, Anaheim, CA, 3 Gilead Sci., Foster City, CA, 4 Gilead Biomet- rics, Foster City, CA. A-1251 Mid-Dosing Versus Trough Concentration of Atazanavir and the Risk of Hyperbilirubinemia and Virological Outcome

S. Lin

1,2 , C. Lu 3 , S. Chang 1 , Y. Chen 1 , C. Hung 2 ; 1 Natl. Taiwan Univ., Taipei, Taiwan, 2 Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 3 Natl. Taiwan Univ. Hosp., Hsinchu, Taiwan. A-1252 Comparing Raltegravir Genital Tract Distribution in HIV- Infected Men and Women E. Dobson 1 , A. Luque 1 , F. Aslam 1 , R. DiCenzo 2,1 ; 1 Univ. of Rochester, Rochester, NY, 2 Albany Coll. of Pharmacy and Hlth. Sci., Albany, NY. A-1253 Raltegravir: Intra-Cellular PharmacokineticsPharmacody- namics

G. Kumar

1 , F. De Salvador-Guillouet 2 , J. Cottalorda 3 , R. Garraffo 4 , P. Roger 5 ; 1 Univ. of Nice Sophia Antipolis, Nice, France, 2 Hosp. L’Archet 1, Nice, France, 3 L’Archet 2, Nice, France, 4 Pasteur, Nice, France, 5 L’Archet 1, Nice, France. A-1254 Comparative Study of the Effects of Anti-TB Drugs and Anti-HIV Drugs on CYP3A4 and P-Glycoprotein

Y. Horita, N. Doi; Janpan Anti-Tuberculosis Assosiation, Res. Inst. of Tuber- culosis, Tokyo, Japan.